Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes
Other Events. Phase 2b REZOLVE-AD Results – 36-Week Blinded Maintenance Period On February 10, 2026, the Company announced results from the 36-week blinded main
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Nektar Therapeutics on February 10, 2026, furnished herewi